奥他万星对美国 10 多年来引起血流感染的革兰阳性病原体的活性：耐药肠球菌亚群的研究重点（2010-2019 年）。
Activity of Oritavancin against Gram-Positive Pathogens Causing Bloodstream Infections in the United States over 10 Years: Focus on Drug-Resistant Enterococcal Subsets (2010-2019).
机构信息
JMI Laboratoriesgrid.419652.d, North Liberty, Iowa, USA.
出版信息
Antimicrob Agents Chemother. 2022 Feb 15;66(2):e0166721. doi: 10.1128/AAC.01667-21. Epub 2021 Nov 22.
Abstract
Oritavancin displayed potent and stable activity (MIC range of 0.06 to 0.5 mg/L) over a 10-year period (2010 to 2019) against Gram-positive pathogens that cause bloodstream infections (BSI), including methicillin-resistant Staphylococcus aureus (MRSA) and resistant subsets of spp. Daptomycin and linezolid were also active against methicillin-resistant S. aureus and vancomycin-resistant (VRE). Only oritavancin and linezolid remained active against Enterococcus faecium isolates displaying an elevated daptomycin MIC (i.e., 2 to 4 mg/L). Proportions of methicillin-resistant S. aureus and vancomycin-resistant within the respective S. aureus and enterococcal populations decreased over this period.
摘要
奥他万古霉素在过去十年（2010 年至 2019 年）对引起血流感染（BSI）的革兰阳性病原体表现出强大且稳定的活性（MIC 范围为 0.06 至 0.5mg/L），包括耐甲氧西林金黄色葡萄球菌（MRSA）和耐药 种的亚群。达托霉素和利奈唑胺对耐甲氧西林金黄色葡萄球菌和万古霉素耐药肠球菌（VRE）也具有活性。只有奥他万古霉素和利奈唑胺对达托霉素 MIC 升高（即 2 至 4mg/L）的粪肠球菌分离株仍具有活性。在这段时间内，耐甲氧西林金黄色葡萄球菌和万古霉素耐药肠球菌在金黄色葡萄球菌和肠球菌种群中的比例有所下降。
相似文献
1
Activity of Oritavancin against Gram-Positive Pathogens Causing Bloodstream Infections in the United States over 10 Years: Focus on Drug-Resistant Enterococcal Subsets (2010-2019).
Antimicrob Agents Chemother. 2022 Feb 15;66(2):e0166721. doi: 10.1128/AAC.01667-21. Epub 2021 Nov 22.
2
In vitro activity of oritavancin alone or in combination against vancomycin-susceptible and -resistant enterococci.
J Antimicrob Chemother. 2019 May 1;74(5):1300-1305. doi: 10.1093/jac/dkz010.
3
Evaluation of Oritavancin Dosing Strategies against Vancomycin-Resistant Enterococcus faecium Isolates with or without Reduced Susceptibility to Daptomycin in an Pharmacokinetic/Pharmacodynamic Model.
Antimicrob Agents Chemother. 2017 Dec 21;62(1). doi: 10.1128/AAC.01873-17. Print 2018 Jan.
4
Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
J Antimicrob Chemother. 2009 Jun;63(6):1191-9. doi: 10.1093/jac/dkp126. Epub 2009 Apr 15.
5
Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
Antimicrob Agents Chemother. 2016 Mar 25;60(4):2352-8. doi: 10.1128/AAC.03006-15. Print 2016 Apr.
6
Epidemiology and risk factors of methicillin-resistant and vancomycin-resistant infections in Zhejiang China from 2015 to 2017.
Antimicrob Resist Infect Control. 2019 May 30;8:90. doi: 10.1186/s13756-019-0539-x. eCollection 2019.
7
Unmet needs and prospects for oritavancin in the management of vancomycin-resistant enterococcal infections.
Clin Infect Dis. 2012 Apr;54 Suppl 3(Suppl 3):S233-8. doi: 10.1093/cid/cir924.
8
Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid.
J Antimicrob Chemother. 2016 Jan;71(1):152-5. doi: 10.1093/jac/dkv302. Epub 2015 Oct 16.
9
Distribution of main Gram-positive pathogens causing bloodstream infections in United States and European hospitals during the SENTRY Antimicrobial Surveillance Program (2010-2016): concomitant analysis of oritavancin in vitro activity.
J Chemother. 2018 Sep;30(5):280-289. doi: 10.1080/1120009X.2018.1516272.
10
Vancomycin-resistant enterococcus bloodstream infection successfully managed with oritavancin and fosfomycin as sequential treatment.
J Chemother. 2024 Feb;36(1):31-34. doi: 10.1080/1120009X.2023.2247205. Epub 2023 Aug 21.
引用本文的文献
1
Glycopeptides: Insights Towards Resistance, Clinical Pharmacokinetics and Pharmacodynamics.
Indian J Microbiol. 2025 Mar;65(1):32-50. doi: 10.1007/s12088-024-01273-y. Epub 2024 Apr 27.
2
Can Oritavancin Be Used for Treatment and/or Suppressive Antimicrobial Therapy of Bone and Joint Infections Caused by Vancomycin-resistant Enterococcus faecium?
Clin Orthop Relat Res. 2025 Mar 14;483(7):1225-33. doi: 10.1097/CORR.0000000000003449.
3
Sentinel Surveillance reveals phylogenetic diversity and detection of linear plasmids harboring and among enterococci collected in the United States.
Antimicrob Agents Chemother. 2024 Nov 6;68(11):e0059124. doi: 10.1128/aac.00591-24. Epub 2024 Oct 15.
4
Fitness costs of Tn1546-type transposons harboring the vanA operon by plasmid type and structural diversity in Enterococcus faecium.
Ann Clin Microbiol Antimicrob. 2024 Jul 8;23(1):62. doi: 10.1186/s12941-024-00722-2.
5
The Molecular Mouse System: A New Useful Tool for Guiding Antimicrobial Therapy in Critically Ill Septic Patients.
Antibiotics (Basel). 2024 Jun 1;13(6):517. doi: 10.3390/antibiotics13060517.
6
Oritavancin Versus Daptomycin for Osteomyelitis Treatment After Surgical Debridement.
Infect Dis Ther. 2024 Mar;13(3):535-547. doi: 10.1007/s40121-024-00925-2. Epub 2024 Feb 29.
7
Therapeutics for Vancomycin-Resistant Enterococcal Bloodstream Infections.
Clin Microbiol Rev. 2023 Jun 21;36(2):e0005922. doi: 10.1128/cmr.00059-22. Epub 2023 Apr 17.
本文引用的文献
1
New-Generation Antibiotics for Treatment of Gram-Positive Infections: A Review with Focus on Endocarditis and Osteomyelitis.
J Clin Med. 2021 Apr 17;10(8):1743. doi: 10.3390/jcm10081743.
2
Resistance in Vancomycin-Resistant Enterococci.
Infect Dis Clin North Am. 2020 Dec;34(4):751-771. doi: 10.1016/j.idc.2020.08.004.
3
A Two-Dose Oritavancin Regimen Using Pharmacokinetic Estimation Analysis.
Drugs Real World Outcomes. 2020 Jun;7(Suppl 1):36-40. doi: 10.1007/s40801-020-00188-6.
4
The Microbiology of Bloodstream Infection: 20-Year Trends from the SENTRY Antimicrobial Surveillance Program.
Antimicrob Agents Chemother. 2019 Jun 24;63(7). doi: 10.1128/AAC.00355-19. Print 2019 Jul.
5
Vital Signs: Epidemiology and Recent Trends in Methicillin-Resistant and in Methicillin-Susceptible Staphylococcus aureus Bloodstream Infections - United States.
MMWR Morb Mortal Wkly Rep. 2019 Mar 8;68(9):214-219. doi: 10.15585/mmwr.mm6809e1.
6
Distribution of main Gram-positive pathogens causing bloodstream infections in United States and European hospitals during the SENTRY Antimicrobial Surveillance Program (2010-2016): concomitant analysis of oritavancin in vitro activity.
J Chemother. 2018 Sep;30(5):280-289. doi: 10.1080/1120009X.2018.1516272.
7
Changes in Prevalence of Health Care-Associated Infections in U.S. Hospitals.
N Engl J Med. 2018 Nov 1;379(18):1732-1744. doi: 10.1056/NEJMoa1801550.
8
Oritavancin in vitro activity against gram-positive organisms from European and United States medical centers: results from the SENTRY Antimicrobial Surveillance Program for 2010-2014.
Diagn Microbiol Infect Dis. 2018 Jun;91(2):199-204. doi: 10.1016/j.diagmicrobio.2018.01.029. Epub 2018 Feb 3.
9
Single Intravenous Dose of Oritavancin for Treatment of Acute Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: Summary of Safety Analysis from the Phase 3 SOLO Studies.
Antimicrob Agents Chemother. 2018 Mar 27;62(4). doi: 10.1128/AAC.01919-17. Print 2018 Apr.
10
Multiple-Dose Oritavancin Evaluation in a Retrospective Cohort of Patients with Complicated Infections.
Pharmacotherapy. 2018 Jan;38(1):152-159. doi: 10.1002/phar.2057. Epub 2017 Dec 11.
Zotero 插件